DIHYDROCODEINE TRIFLUOROACETATE
DIHYDROCODEINE TRIFLUOROACETATE Basic information
- Product Name:
- DIHYDROCODEINE TRIFLUOROACETATE
- Synonyms:
-
- 4,5-alpha-epoxy-3-methoxy-17-methyl-morphinan-6-alpha-o
- 4,5alpha-Epoxy-3-methoxy-17-methylmorphinan-6alpha-ol
- 6-alpha-hydrocodol
- 6alpha-Hydrocodol
- 6-Hydroxy-3-methoxy-N-methyl-4,5-epoxymorphinan
- 7,8-dihydro-codein
- 7,8-Dihydrocodeine
- 8,14-Dihydroneopine
- CAS:
- 125-28-0
- MF:
- C20H24F3NO4
- MW:
- 399.4
- EINECS:
- 204-732-3
- Mol File:
- 125-28-0.mol
DIHYDROCODEINE TRIFLUOROACETATE Chemical Properties
- Melting point:
- 112-113°
- Boiling point:
- bp15 248°
- Density
- 1.1412 (rough estimate)
- refractive index
- 1.5740 (estimate)
- Flash point:
- 9℃
- storage temp.
- 2-8°C
- solubility
- DMF: 20 mg/ml; DMF:PBS(pH 7.2)(1:1): 0.5 mg/ml; DMSO: 10 mg/ml
- form
- A neat solid
- EPA Substance Registry System
- Morphinan-6-ol, 4,5-epoxy-3-methoxy-17-methyl-, (5?,6?)- (125-28-0)
Safety Information
- Hazard Codes
- F,T
- Risk Statements
- 11-23/24/25-39/23/24/25
- Safety Statements
- 7-16-36/37-45
- RIDADR
- UN1230 - class 3 - PG 2 - Methanol, solution
DIHYDROCODEINE TRIFLUOROACETATE Usage And Synthesis
Description
Dihydrocodeine (Item No. 37884) is an analytical reference standard categorized as an opioid.1 Dihydrocodeine is an active metabolite of hydrocodone (Item Nos. ISO60144 | 15461 | 22166).2 Formulations containing dihydrocodeine have been used in the treatment of severe pain and have been associated with misuse and polypharmacy-related overdose.3 Dihydrocodeine is regulated as a Schedule II compound in the United States. This product is intended for research and forensic applications.WARNING This product is not for human or veterinary use.
Description
Dihydrocodeine (CRM) (Item No. ISO60142) is a certified reference material categorized as an opioid.1 Dihydrocodeine is an active metabolite of hydrocodone (Item Nos. ISO60144 | 15461 | 22166).2 Formulations containing dihydrocodeine have been used in the treatment of severe pain and have been associated with misuse and polypharmacy-related overdose.3 Dihydrocodeine is regulated as a Schedule II compound in the United States. Dihydrocodeine (CRM) (Item No. ISO60142) is provided as a DEA exempt preparation. This product is intended for research and forensic applications.WARNING This product is not for human or veterinary use.
Description
Dihydrocodeine (Item No. 15460) is an analytical reference material categorized as an opioid.1 Dihydrocodeine is an active metabolite of hydrocodone (Item Nos. ISO60144 | 15461 | 22166).2 Formulations containing dihydrocodeine have been used in the treatment of severe pain and have been associated with misuse and polypharmacy-related overdose.3 Dihydrocodeine is regulated as a Schedule II compound in the United States. This product is intended for research and forensic applications.WARNING This product is not for human or veterinary use.
Originator
Bicodein,Uquifa
Definition
ChEBI: Dihydrocodeine is a morphinane alkaloid.
Manufacturing Process
The codein was reduced by hydrogen in the presence catalyst Pt (or Pd, or Ni)
and 7,8-dihydrocodein was obtained.
To the 7,8-dihydrocodein tartaric acid was added and mixed, in the result 7,8-
dihydrocodein bitartrate was obtained.
Therapeutic Function
Antitussive, Narcotic analgesic
Safety Profile
Poison by ingestion, intravenous, and subcutaneous routes. Human systemic effects by ingestion and subcutaneous routes: somnolence, miosis (pupillary constriction), and respiratory depression. An analgesic. Can cause drug dependency with repeated doses. When heated to decomposition it emits toxic fumes of NOx. See also CODEINE.